Müllerova Hana, Gelhorn Heather, Wilson Hilary, Benson Victoria S, Karlsson Niklas, Menjoge Shailendra, Rennard Stephen I, Tabberer Maggie, Tal-Singer Ruth, Merrill Debora, Jones Paul W
Research and Development, GlaxoSmithKline, Uxbridge, United Kingdom.
Evidera, Bethesda, Maryland.
Chronic Obstr Pulm Dis. 2017 Mar 28;4(2):141-149. doi: 10.15326/jcopdf.4.2.2017.0131.
We aimed to estimate the usefulness of a disease specific health status measure, the St George's Respiratory Questionnaire (SGRQ), to predict outcomes in patients with chronic obstructive pulmonary disease (COPD). Individual patient-data of 12043 patients from long-term randomized clinical trials (2-4 years' duration) in the COPD Biomarkers Qualification Consortium database were analyzed. The adverse COPD outcomes were: exacerbations of COPD, hospital admissions due to exacerbation and all-cause mortality. Cox proportional hazards regression was used to calculate adjusted hazard ratios (HR) and 95% confidence intervals (CIs) for quartiles of SGRQ scores at baseline and time to first event, and time from first to second event, where appropriate. The risk of adverse COPD outcomes increased with each increasing quartile of SGRQ score for all time to first event analyses. When comparing the lowest versus the highest quartile, the event risk (HRs [95% CIs]) increased by 40% for exacerbations (1.40 [1.29, 1.51]); 2-fold for hospital admissions (2.01 [1.78, 2.28]) and more than 2-fold for all-cause mortality (2.30 [1.91, 2.78]). For second event analyses in a subset of eligible patients, these trends persisted albeit with reduced risk estimates for exacerbations. Among patients with COPD, health status measured by a SGRQ score predicted exacerbations of COPD, hospital admissions due to exacerbations and their recurrence and death after adjustment. These data support the rationale for a health status measure use as a drug development tool and suggest that a health status measure may also have a role in risk assessment for COPD patients in routine medical care.
我们旨在评估一种疾病特异性健康状况测量工具——圣乔治呼吸问卷(SGRQ)对慢性阻塞性肺疾病(COPD)患者预后的预测作用。分析了慢性阻塞性肺疾病生物标志物鉴定联盟数据库中来自长期随机临床试验(为期2至4年)的12043例患者的个体患者数据。慢性阻塞性肺疾病的不良预后包括:慢性阻塞性肺疾病急性加重、因急性加重导致的住院以及全因死亡率。采用Cox比例风险回归分析,计算基线时SGRQ评分四分位数至首次事件发生时间、以及适当时从首次事件至第二次事件发生时间的校正风险比(HR)和95%置信区间(CI)。在所有首次事件发生时间分析中,慢性阻塞性肺疾病不良预后的风险随SGRQ评分四分位数的增加而升高。比较最低四分位数与最高四分位数时,急性加重的事件风险(HR[95%CI])升高40%(1.40[1.29,1.51]);因急性加重住院的事件风险升高2倍(2.01[1.78,2.28]);全因死亡率升高超过2倍(2.30[1.91,2.78])。在符合条件的患者亚组中进行的第二次事件分析中,这些趋势依然存在,尽管急性加重的风险估计有所降低。在慢性阻塞性肺疾病患者中,通过SGRQ评分测量的健康状况可预测慢性阻塞性肺疾病急性加重、因急性加重导致的住院及其复发以及调整后的死亡情况。这些数据支持将健康状况测量作为药物研发工具的基本原理,并表明健康状况测量在常规医疗中对慢性阻塞性肺疾病患者的风险评估中也可能发挥作用。